About Us and ALS Treatment Testimonials
The Foundation of CGTI and Its Mission
The Foundation for Cell, Gene and Tissue Innovations (CGTI) is a 501(c)3 Texas non-profit that accepts and distributes tax-deductible donations to support its mission to provide support for research and education, including Clinical Trials, that explore the rationale and clinical use of novel disease therapies to treat human diseases. Clinical Trials will focus on at-home and close-to-home care. Educational support efforts, such as new cell therapies to treat ALS, are targeted to all stakeholders, including patients, caregivers, medical professionals, scientists, innovators, the general public, and others who want to make new, science-based therapies available to patients.
Dr. Mary Pat Moyer: Scientist, Entrepreneur, Innovator and Leader
Dr. Mary Pat Moyer is a scientist, entrepreneur, educator, and recognized innovator leading the way for new cell therapies and their formulation and delivery available for at-home and close-to-home care. As the Chief Science Officer, she directs INCELL's research, product development, biomanufacturing and Clinical Trials programs. She also serves as a University of Texas UT Health San Antonio Professor of Surgery, Translational Sciences, and Cell Systems and Anatomy. She is an elected member (2019) of the National Academy of Engineering in the Bioengineering section and was honored with a 2024 selection as a Fellow of the Texas A&M University Hagler Institute of Advanced Sciences. With over 250 publications, worldwide presentations and community activism, Moyer brings more than 56 years' multidisciplinary experience in human cell biotechnology, cell culture, cell/tissue banking, regenerative medicine, cancer, microbiology, infectious diseases, and education.
Dr. Peter Edenhoffer, Neurologist and Medical Scientist
Dr. Peter J. Edenhoffer, MD, is a practicing Texas Neurologist and an active researcher as the Clinical Investigator for ALS-PACT INDs and other on-going and planned studies. He has published work relevant to cell therapies, aging and clinical innovations, including medical devices, and is taking graduate science courses to expand his knowledge and clinical trials performance. He provides physician care to patients with neurological diseases and disorders, including ALS. He is also an entrepreneur-inventor designing improved delivery of cells, cell-derived, and other therapies. He has regulatory, cGCP, IRB and statistics training relevant to bringing leadership to therapeutic clinical trials.
Testimonial of MDA, the ALS Patient Treated with ALS-PACT
ALS Patient, MDA: " I have now been living with ALS for almost 20 years and have seen my physical health slowly decline while mentally I am as sharp as ever. I have been working with Dr. Moyer for about 6 years to help with designing the study and was honored to be her first individual study patient for treating ALS. I am happy to do anything I can to provide information needed to find a cure for this terrible disease. I have definitely seen and felt some improvements and am very optimistic that Dr. Moyer might be on the right track.
Testimonial: MDA's Wife and Caregiver
"My husband has suffered with this disease since 2007. It has been difficult to see him struggle physically with day-to-day tasks even though his mind is fully intact. Over these many years, I have developed a keen sense of what he is saying; he has no trouble understanding me. He has now completed his 14th treatment and the cell therapy treatments have been helping his condition. Since December 2023 (around Visit 8), I have observed him standing upright with his walker and walking slowly and shakily for several steps. As he has been unable to walk any distance for years, this was extremely promising. I also see that he is drooling and choking less which makes him happier and he seems to be in better spirits."
Testimonial: MDA's Mother and Caregiver
"To see your child struggle and succumb to ALS is heartbreaking. Over the past year, we have watched my son make noteworthy improvements with INCELL ALS-PACT cell therapies. At about the 8th treatment, he could hold a spoon and with certain foods was able to feed himself minimally. Prior, his caregivers always fed him. He can now walk for short distances, with last count as 46 steps using his walker. This was never possible before therapy. He is not choking as frequently as before, and his drooling is infrequent. He has been able to hold a pen and with effort, write his name. Mentally, these treatments have lifted his spirits. He has been very positive and happy and pushes himself to complete his exercises."
Testimonial: MDA's Primary Daily Caregiver
"I am MDA’s main caregiver five (5) days a week in the mornings and late afternoon into the evening. I provide MDA’s total care, meals, hygiene services, exercises, take him to doctor appointments, take him for his ALS-PACT cell therapies, dress him for the day and then get him ready for bed. For the study, INCELL provided equipment, exercise lists, evaluation and monitoring forms and instructions for the testing and supportive activities for MDA's cell treatments. I record test results to send to INCELL and provide other supportive treatments to reduce pain and increase circulation to help "wake up" the communications between the nerves and muscles. Both MDA and I have observed improvements in his strength, agility, and his balance. He has been confident enough to do some squats from the bed using his walker. MDA will now walk for several steps with his walker and then return to his bed. I am always beside him just in case. He is drooling less, and doesn’t choke as much as before, while eating. I know that the INCELL Team respects and supports the role of Caregivers, and I am happy to support the important work INCELL is doing to help ALS patients."
Ways to Help
ALS: Amyotrophic Lateral Sclerosis, a Progressive Neural Disease
Educating, Developing and Manufacturing Innovative Cell, Gene and Tissue Therapies
Other Neurodegenerative Diseases; Injury or Trauma of Brain or Peripheral Nerves
A progressive neurodegenerative disease, ALS is characterized by disrupted connections of nerves to muscles, causing weak and wasting muscles, decreased strength, loss of hand use, and difficulties in speech, swallowing, standing, walking, mobility, breathing and self-care. Pain types, intensity levels and location vary greatly among patients and mental health and quality of life are diminished.
Other Neurodegenerative Diseases; Injury or Trauma of Brain or Peripheral Nerves
Educating, Developing and Manufacturing Innovative Cell, Gene and Tissue Therapies
Other Neurodegenerative Diseases; Injury or Trauma of Brain or Peripheral Nerves
Neurodegenerative diseases are chronic conditions that damage and destroy parts of the nervous system, particularly the brain. Some result from injury/trauma, or genetic predisposition, most causes are unknown. Some types of neurodegenerative diseases include Alzheimer's, Parkinson's, multiple sclerosis, dementia, or ALS. Brain or peripheral nerve injury or trauma have many causes.
Educating, Developing and Manufacturing Innovative Cell, Gene and Tissue Therapies
Educating, Developing and Manufacturing Innovative Cell, Gene and Tissue Therapies
Educating, Developing and Manufacturing Innovative Cell, Gene and Tissue Therapies
The mission of providing education and training about developing, manufacturing and therapy of innovative cell, gene and tissue products. These translational science efforts are targeted to patients, caregivers, medical professionals, scientists, innovators, the general public, and others implementing rational, science-based CGTI therapies through at-home or close-to-home treatments and testing.
Contact Us
FCGTI.org
Foundation for Cell Gene and Tissue Innovations, 12734 Cimarron Path, San Antonio TX 78249; Phone: 210-877-0111
Open today | 09:00 am – 05:00 pm |
